William Damsky

Associate Professor of Dermatology

Yale University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (11)

Year:

2026

Identifying factors that mediate successful anticancer immune responses is necessary to improve outcomes for patients with advanced cancers. In this study, we performed single-cell RNA sequencing on mouse melanomas experiencing successful and unsuccessful immune responses and discovered a prominent ferroptosis signature in tumors undergoing immune-mediated regression. Pairing ferroptosis inducers and inhibitors with immunotherapies ex vivo and in vivo highlighted a central role for ferroptosis in stimulating the antimelanoma immune response. In coculture models, CD8 + T cells drove melanoma cell ferroptosis by altering the expression of glutathione peroxidase 4 (GPX4), a crucial antioxidant enzyme known for its role in preventing lipid peroxidation. Direct contact between tumor cells and CD8 + T cells was needed to sustain GPX4 downregulation over time, resulting in ferroptotic cell death. Finally, single-cell RNA sequencing data from human melanoma tumors responding to immunotherapy revealed a ferroptosis signature that mirrors the mouse model. Together, these results offer crucial insights into the role of ferroptosis in antitumor immunity and highlight the potential of modulating ferroptosis to enhance immunotherapy responses. Significance: CD8 + T cells directly interact with melanoma cells to downregulate the essential antioxidant enzyme GPX4 and stimulate ferroptosis, which is a crucial driver of immune cell-mediated melanoma clearance.

Year:

2025

Despite recent advances in the treatment of melanoma, many patients with metastatic disease still succumb to their disease. To identify tumor-intrinsic modulators of immunity to melanoma, we performed a whole-genome CRISPR screen in melanoma and identified Setdb1 as well as all components of the human silencing hub complex. We found that loss of Setdb1 leads to increased immunogenicity and complete tumor clearance in a CD8 + T cell–dependent manner. Mechanistically, loss of Setdb1 causes de-repression of endogenous retroviruses (ERV) in melanoma cells and triggers tumor cell–intrinsic type I IFN signaling, upregulation of MHC-I expression, and increased CD8 + T-cell infiltration. Importantly, spontaneous immune clearance observed in Setdb1 −/− tumors results in subsequent protection from other ERV-expressing tumor lines, supporting the functional antitumor role of ERV-specific CD8 + T cells found in the Setdb1 −/− microenvironment. Blocking the type I IFN receptor in mice grafted with Setdb1 −/− tumors decreases immunogenicity by decreasing MHC-I expression, leading to decreased T-cell infiltration and increased melanoma growth, comparable with Setdb1 wt tumors. Together, these results provide key in vivo evidence of a critical role for Setdb1 and type I IFNs in generating an inflamed tumor microenvironment and potentiating tumor cell–intrinsic immunogenicity in melanoma. This study further emphasizes regulators of ERV expression and type I IFN expression as potential therapeutic targets for augmenting anticancer immune responses.

Year:

2025

Molecular profiling on biopsies from 31 patients with Grover disease (GD) shows increased expression of interleukin 13 (a T helper 2 cell cytokine) to be a hallmark of GD. In a supportive retrospective series of nine patients with treatment-refractory GD, all improved with dupilumab. This work helps establish GD as a type 2 immune disorder.

Year:

2025

Checkpoint inhibitors have revolutionized cancer treatment, but resistance remains a significant clinical challenge. Myeloid cells within the tumor microenvironment can modulate checkpoint resistance by either supporting or suppressing adaptive immune responses. Using an anti–PD-1–resistant mouse melanoma model, we show that targeting the myeloid compartment via CD40 activation and CSF1R blockade in combination with anti–PD-1 results in complete tumor regression in a majority of mice. This triple therapy combination was primarily CD40 agonist-driven in the first 24 hours after therapy and showed a similar systemic cytokine profile in human patients as was seen in mice. Functional single-cell cytokine secretion profiling of dendritic cells (DC) using a novel microwell assay identified a CCL22 + CCL5 + IL12-secreting DC subset as important early-stage effectors of triple therapy. CD4 + and CD8 + T cells are both critical effectors of treatment, and systems analysis of single-cell RNA sequencing data supported a role for DC-secreted IL12 in priming T-cell activation and recruitment. Finally, we showed that treatment with a novel IL12 mRNA therapeutic alone was sufficient to overcome PD-1 resistance and cause tumor regression. Overall, we conclude that combining myeloid-based innate immune activation and enhancement of adaptive immunity is a viable strategy to overcome anti–PD-1 resistance.

Year:

2025

Purpose: IFN signaling in the tumor microenvironment is a critical determinant of both response and resistance of cancer to immune checkpoint inhibitors (ICI). We hypothesized that distinct patterns of IFN signaling in melanoma are associated with clinical response or resistance to ICIs. Experimental Design: Two tissue microarrays containing samples from 97 patients with metastatic melanoma who received nivolumab, pembrolizumab, or a combination of ipilimumab and nivolumab at Yale New Haven Hospital between 2011 and 2017 were randomized into discovery and validation cohorts. Samples were stained and visualized using multiplexed immunofluorescence microscopy for STAT1, STAT1 phosphorylated at Y701 (pSTAT1 Y701 ), and PD-L1, and signals were quantified using the automated quantitative analysis method of quantitative immunofluorescence. Treatment response was assessed using RECIST, and overall survival was analyzed. For in vitro studies, human melanoma cell lines were stimulated with IFNγ and IFNβ, and Western blotting was performed. Results: Pretreatment STAT1 levels were higher in responders to ICIs [complete response/partial response/stable disease (SD) for > 6 months] than in nonresponders (SD Y701 and PD-L1. When combining STAT1 and PD-L1 markers, patients with STAT1 high PD-L1 low tumors had improved survival compared with those with STAT1 low PD-L1 high tumors. Conclusions: STAT1 may better predict melanoma response to ICIs than current strategies, and combined STAT1 and PD-L1 biomarkers may provide insight into IFN-responsive versus IFN-resistant states.

Year:

2025

Effective cancer immunotherapies restore anti-tumor immunity by rewiring cell-cell communication. Treatment-induced changes in communication can be inferred from single-cell RNA-sequencing (scRNA-seq) data, but current methods do not effectively manage heterogeneity within cell types. Here we developed a computational approach to efficiently analyze scRNA-seq-derived, single-cell-resolved cell-cell interactomes, which we applied to determine how agonistic CD40 (CD40ag) alters immune cell crosstalk alone, across tumor models, and in combination with immune checkpoint blockade (ICB). Our analyses suggested that CD40ag improves responses to ICB by targeting both immuno-stimulatory and immunosuppressive macrophage subsets communicating with T cells, and we experimentally validated a spatial basis for these subsets with immunofluorescence and spatial transcriptomics. Moreover, treatment with CD40ag and ICB established coordinated myeloid-T cell interaction hubs that are critical for reestablishing antitumor immunity. Our work advances the biological significance of hypotheses generated from scRNA-seq-derived cell-cell interactomes and supports the clinical translation of myeloid-targeted therapies for ICB-resistant tumors.

Year:

2024

Background Atopic dermatitis (AD) has been associated with psychiatric comorbidities. Objectives To characterize the association between AD and bipolar disorder (BPD) with a case–control study of the National Institutes of Health All of Us Research Program. Methods We used Systematized Nomenclature of Medicine diagnostic codes to identify cases of AD. Four age-, sex- and race/ethnicity-matched controls were found for each case using propensity score matching. After controlling for age, sex, race/ethnicity, income, smoking status and depression, the relationship between AD and BPD was evaluated using logistic regression. Results We identified 13 431 AD cases and 53 724 matched controls. Participants with AD were more likely than controls to have BPD (7.8% vs. 4.6%, P < 0.001). After adjusting for demographics and comorbidities, we observed a significant association (odds ratio 1.49, 95% confidence interval 1.37–1.62; P < 0.001). Conclusions Compared with individuals without AD, individuals with AD have 1.49-fold increased odds of having BPD. Further investigation is needed to gain a better understanding of this association.

Year:

2024

Purpose: Interferon (IFN) signaling in the tumor microenvironment is a critical determinant of both response and resistance of cancer to immune checkpoint inhibitors (ICIs). We hypothesized that distinct patterns of IFN signaling in melanoma are associated with clinical response or resistance to ICIs. Experimental Design: Two Tissue Microarrays (TMAs) containing samples from 97 patients with metastatic melanoma who received nivolumab, pembrolizumab, or a combination of ipilimumab and nivolumab at Yale New Haven Hospital between 2011-2017 were randomized into discovery and validation cohorts. Samples were stained and visualized using multiplexed immunofluorescence microscopy for STAT1, STAT1 phosphorylated at Y701 (pSTAT1 Y701 ), and PD-L1, and signals were quantified using the AQUA method of quantitative immunofluorescence. Treatment response was assessed using RECIST criteria, and overall survival was analyzed. For in vitro studies, human melanoma cell lines were stimulated with IFNγ and IFNβ, and Western blotting was performed. Results: Pre-treatment STAT1 levels were higher in responders to ICIs (CR/PR/SD for > 6 months) than in non-responders (SD Y701 and PD-L1. When combining STAT1 and PD-L1 markers, patients with STAT1 high PD-L1 low tumors had improved survival compared with those with STAT1 low PD-L1 high tumors. >Conclusions: STAT1 may better predict melanoma response to ICIs than current strategies, and combined STAT1 and PD-L1 biomarkers may provide insight into IFN-responsive versus IFN-resistant states.

Year:

2024

Checkpoint inhibitors have revolutionized cancer treatment, but resistance remains a significant clinical challenge. Myeloid cells within the tumor microenvironment can modulate checkpoint resistance by either supporting or suppressing adaptive immune responses. Using an anti-PD-1-resistant mouse melanoma model, we show that targeting the myeloid compartment via CD40 activation and CSF1R blockade in combination with anti-PD-1 results in complete tumor regression in a majority of mice. This triple therapy combination was primarily CD40 agonist-driven in the first 24 hours post-therapy and showed a similar systemic cytokine profile in human patients as was seen in mice. Functional single-cell cytokine secretion profiling of dendritic cells (DCs) using a novel microwell assay identified a CCL22+CCL5+ IL12-secreting DC subset as important early-stage effectors of triple therapy. CD4+ and CD8+ T cells are both critical effectors of treatment, and systems analysis of single-cell RNA-sequencing data supported a role for DC-secreted IL12 in priming T-cell activation and recruitment. Finally, we showed that treatment with a novel IL12 mRNA therapeutic alone was sufficient to overcome PD-1 resistance and cause tumor regression. Overall, we conclude that combining myeloid-based innate immune activation and enhancement of adaptive immunity is a viable strategy to overcome anti-PD-1 resistance.

Year:

2024

Year:

2024

Collaborators (22)

Qin Yan

Anthony N. Brady Professor of Pathology

Yale University

UNITED STATES
View details

Benjamin E. Turk

Yale University School of Medicine

UNITED STATES
View details

Goran Micevic

Yale University

UNITED STATES
View details

Susan Kaech

Director & Professor

Salk Institute for Biological Studies

UNITED STATES
View details

Kathryn Miller-Jensen

Associate Professor

Yale University

UNITED STATES
View details

Wei Wei

Assistant Professor

Yale University School of Medicine

UNITED STATES
View details

Constanze Jonak

Medical University of Vienna

AUSTRIA
View details

David Calderwood

Yale University School of Medicine

UNITED STATES
View details

Harriet Kluger

Yale University School of Medicine

UNITED STATES
View details

Marcus Bosenberg

Professor

Yale University

UNITED STATES
View details

Thazin Nwe Aung

Associate Research Scientist

Yale University

UNITED STATES
View details

Mario Sznol

Professor of Clinical

University of Miami

UNITED STATES
View details

Akiko Iwasaki

Professor

Yale University School of Medicine

UNITED STATES
View details

Esther von Stebut

Head of department

University Hospital

GERMANY
View details

Patrick M. Brunner

Associate Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Christine Bangert

-

AUSTRIA
View details

Ramon Klein Geltink

Assistant Professor

The University of British Columbia

CANADA
View details

Rong Fan

Harold Hodgkinson Professor of Biomedical Engineering

Yale University

UNITED STATES
View details

Simon F Roy

Assistant Professor

McGill University

CANADA
View details

David E Sanin

Assistant Professor

Johns Hopkins University

UNITED STATES
View details

Jan-Wilm Lackmann

Head of Proteomics Facility

University of Cologne

GERMANY
View details

David Rimm

Professor

Yale University

UNITED STATES
View details